entertainment -WSS

entertainment

author：leisure time 2025-09-02 08:20:30 - browse：1677

Immunofluorescence image shows CD4+ (green) and CD8+ (yellow) T cells in the microenvironment of a head and neck squamous cell carcinoma. — This immunofluorescence image shows T cells (in green and yellow) in the microenvironment of a head and neck squamous cell carcinoma. Allen Lab/NCI/NIH

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial.

The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

But the Dutch drugmaker on Tuesday withheld additional information from the study related to the safety and durability of petosemtamab’s tumor responses, pending presentation at the annual meeting of the American Society of Clinical Oncology on June 3.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： AI can’t replace a physician’s gut feeling

focus

WSS

STAT Virtual Event: The State of Biosimilars: What to Watch

Abortion clinic in Cancun will cater to Americans

As digital health tech proliferates, a new institute aims to cut through hype

MoonLake credibility takes another hit with mid

MoonLake credibility takes another hit with mid

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

leisure time

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Anesthesiologist group: stop taking Ozempic before surgery

Free speech concerns arise in wake of journal editor Eisen's firing

Hepatitis C has a cure — but many Americans still lack access to it

How Medicaid coverage policies for immigrants impact new moms

Heart attack and stroke risk calculators need revising

How Medicaid coverage policies for immigrants impact new moms

BioMarin wins approval for gene therapy to treat hemophilia A

A public scorecard can help hold safety

At least 13 dead in Texas as scorching temps continue

Why hospitals are withdrawing from US News rankings

focus

Doctors find melanoma drugs effective against rare brain cancer

Custom gene therapy hints at new path for rare disease treatments

Group opposing PBM reform sets lobbying record

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Group opposing PBM reform sets lobbying record

A public scorecard can help hold safety

leisure time

focus

focus

hotspot